Abstract:Objective: To identify the influencing factors of thrombosis besides antiphospholipid antibodies in patients with antiphospholipid syndrome (APS). Methods: The 169 patients diagnosed with APS were enrolled according to the current APS classification criteria from January 2003 to August 2017 in Peking University People's Hospital. There were 23 males and 146 females with a mean age of (41±15) years. Antiphospholipid antibodies, including anticardiolipin (aCL), anti-β2glycoprotein-1 (β2GP1) antibodies and antibodies to the phosphatidylserine-prothrombin complex (aPS/PT), were determined by enzyme-linked immunosorbent assay (ELISA) methods. Lupus anticoagulant (LA) was identified using the STA Compact coagulation testing system. The differences of clinical and laboratory characteristics between patients with and without thrombosis were analyzed (100 cases and 69 cases, respectively). The influencing factors for thrombosis in patients with APS were determined using binary logistic regression. Results: Compared with patients without thrombosis, patients with thrombosis were older and had a longer disease duration ((45±17) years vs (35±9) years and M(Q1, Q3) 12.0(3.8, 84.0) months vs 48.0(12.0, 108.0) months, both P<0.05). The percentage of male, primary APS, smoking, low blood platelet count, hypertension, and diabetes in patients with thrombosis were significantly higher than those in patients without thrombosis (all P<0.05). Similarly, the rates of antinuclear antibodies positive, aCL positive, aPS/PT-IgM positive, and aPS/PT-IgG positive in patients with thrombosis were significantly higher than those in patients without thrombosis (all P<0.05). The levels of D-dimer in patients with thrombosis were significantly higher than that in patients without thrombosis (P<0.05). There was significant difference in global anti-phospholipid syndrome score (GAPSS) between patients with and without thrombosis (P<0.05). The GAPSS score was also significantly higher in patients with arterial thrombosis than that in patients with venous thrombosis (P<0.05). Smoking and D-dimer levels were independent influencing factors for thrombosis in patients with APS (smoking: OR=11.222, 95%CI:1.119-112.544, P=0.040, D-dimer levels: OR=1.002, 95%CI: 1.000-1.003, P=0.037). Conclusions: Thrombotic APS patients are older and have a longer suffering duration, a higher ratio of male, primary APS, smoking, hypertension, lower blood platelet count, diabetes, higher GAPSS scale, and higher D-dimer levels. Smoking and D-Dimer levels may be independent risk factors for thrombosis in patients with APS.

Interpreting high levels of unfolded Von Willebrand Factor in patients with the antiphospholipid syndrome

Platelets and Thrombotic Antiphospholipid Syndrome

Cellular and Molecular Mechanisms of Anti-Phospholipid Syndrome

Platelet distribution width is highly associated with thrombotic events in primary antiphospholipid syndrome

Interaction of antiphospholipid antibodies with endothelial cells in antiphospholipid syndrome

Targeting thromboinflammation in antiphospholipid syndrome

Oxidised low-density lipoprotein and antibodies against oxidised low-density lipoprotein in patients with antiphospholipid syndrome

Influence of anticardiolipin and anti‐β2 glycoprotein I antibody cutoff values on antiphospholipid syndrome classification

[Analysis of Risk Factors in Development of Thrombosis in Patients with Antiphospholipid Syndrome].

Noncriteria antiphospholipid antibodies in antiphospholipid syndrome

Von Willebrand factor deficiency and atherosclerosis

Unfolded Von Willebrand Factor Binds Protein S and Reduces Anticoagulant Activity

The Pathophysiology of The Antiphospholipid Syndrome: A Perspective From The Blood Coagulation System

[Influencing Factors of Thrombosis Besides Antiphospholipid Antibodies in Patients with Antiphospholipid Syndrome].

Biological markers of high risk of thrombotic recurrence in patients with antiphospholipid syndrome: A literature review

Anti–Neutrophil Extracellular Trap Antibodies and Impaired Neutrophil Extracellular Trap Degradation in Antiphospholipid Syndrome

Determinants of Risk for Venous and Arterial Thrombosis in Primary Antiphospholipid Syndrome and in Antiphospholipid Syndrome with Systemic Lupus Erythematosus

Increased Adhesive Potential of Antiphospholipid Syndrome Neutrophils Mediated by β2 Integrin Mac‐1

The Issue of the Antiphospholipid Antibody Syndrome

Deciphering the clinical significance of longitudinal antiphospholipid antibody titers

Risk factors in antiphospholipid antibody-associated valvular heart disease: A 383-patient cohort study